Analystreport

Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target raised by analysts at B. Riley from $6.00 to $8.00.

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806